MyFinsight
Home
Blog
About
Proceeds from the sale of
common stock and...
$25,196,142
(45.55%↑ Y/Y)
Proceeds from exercise of
common stock warrants
$4,316,371
(-74.35%↓ Y/Y)
Net cash provided by
financing activities
$26,604,364
(-20.41%↓ Y/Y)
Canceled cashflow
$2,908,149
Net increase
(decrease) in cash and cash...
$3,493,842
(157.97%↑ Y/Y)
Canceled cashflow
$23,110,522
Payment of issuance
costs
$1,930,539
Payment of financing
costs
$977,610
Loss (gain) from
change in fair value of...
$7,036,009
(117.44%↑ Y/Y)
Prepaid expenses and
other current assets
-$1,854,103
(69.96%↑ Y/Y)
(gain) loss on
extinguishment of debt
-$1,329,048
Loss (gain) from
change in fair value of...
$1,103,000
(-80.78%↓ Y/Y)
Accounts receivable
-$1,075,537
(-161.41%↓ Y/Y)
Stock-based compensation
$791,670
(-88.81%↓ Y/Y)
Loss (gain) on equity
method investment
-$41,012
(59.23%↑ Y/Y)
Amortization
$13,791
(-84.21%↓ Y/Y)
Net cash used in
operating activities
-$21,010,522
(46.74%↑ Y/Y)
Net cash used in
investing activities
-$2,100,000
Canceled cashflow
$13,244,170
Net loss
-$20,319,271
(58.64%↑ Y/Y)
Accounts payable
-$6,460,902
(-494.97%↓ Y/Y)
Investment in joint venture
$2,100,000
Accrued expenses
-$5,760,414
(-524.97%↓ Y/Y)
Inventory
$1,699,288
(-58.82%↓ Y/Y)
Operating lease
liabilities
-$14,817
(60.09%↑ Y/Y)
Back
Back
Cash Flow
Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc. (OTLK)
source: myfinsight.com